11.09.22 Zetomipzomib(KZR-616), A First-in-Class, Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis: Results from the Completed Phase 2 Portion of the MISSION Study. American College of Rheumatology Convergence 2022 (ACR 2022).
